Document YDkgzp84Jn1gGv60VYwYGJqvK

^ D is trib u te d (1) CTFA, SAC Committee on 3 / 18776" (2) CTFA Talc Sub-Committee on 3/31/76 PLAINTIFF'S EXHIBIT WCD-403 SUMMARY REPORT OF CTFA TALC SUB-COMMITTEE CTFA Talc Sub-Committee met on March 11, 1976 to review recent press re p o rt p e rta in in g to analysts o f talcum powder products. As a re s u lt o f inform ation c o lla te d from the attending company representatives, the fo llo w in g fa c ts were ascertained: 1. The samples were analyzed by Sinai in 1973, 2. Samples were confirmed as pre-1971 production w ith one product which has not been manufactured since the end o f World War I I , 3. The asbestos a n a ly tic a l re s u lts o f Sinai are in c o n f lic t w ith those determined on the same samples by Dr. Pooley, a C a rd iff s c ie n tis t o f world renov/n. Mt. Sinai reported ten samples as containing up to 20% asbestos, whereas Pooley detected asbestiform mineral in only fiv e samples and a t considerably lower le v e ls . Based on the above s itu a tio n the cornmittee f e l t th a t i t would be important to put th is s itu a tio n in proper perspective by: 1, Presenting summary data to FDA to a ffirm the responsible action which has been pursued by our in d u stry since 1972 when the asbestos concern f i r s t surfaced - Plan "A" 2, Considering a sampling o f current in d u stry production and subm itting th is to analysis by FDA, Mt. Sinai and inde pendent a n a ly tic a l la b o ra to rie s - Plan "B" - to be c a rrie d out only i f Plan "A" were found to be in s u ffic ie n t. A ction taken to date has been the fo llo w in g : 1. Plan HA" was executed immediately over the weekend and on March 15, le tte r s were received from the fo llo w in g companies and c r i t i c a l l y reviewed: Avon Chesebrough Ponds Colgate Palmolive Coty Cyprus Minerals Faberge Johnson & Johnson Walter FicCrone Associates S te rlin g Drug W hittaker, Clark S Daniels Approximately 4,000 analyses have been reviewed covering the period as e arly as 1971, Goodhue WCD 000240 - 2- 2. The ta lc sub-committee met w ith Dr. Schaffner and his s t a f f on the afternoon o f March 15 to summarise and present these documents, FDA was s u ita b ly impressed but urged consideration fo r the in c lu s io n o f a sampling plan in the CTFA Talc Standard. In consideration o f the voiced p ra c tic a l d i f f i c u lt i e s , due to in d iv id u a l s itu a tio n s , Dr. Schaffner, as an a lte rn a tiv e , suggested the voluntary submission o f perio d ic reports, on ta lc analyses. We were advised th a t the FDA has analyzed seventy s ix samples o f ta lc products In 1975 and has not detected asbestos, according to t h e ir methods o f a n a ly s is , "DTA and Optical Microscopy", Samples o f these products im plicated by Sinai have been offered by the FDA to Mt. Sinai lab o ra to rie s fo r th e ir analysis. The Revised Talc Standard was submitted to the CTFA headquarters on March 18, 1976 fo r p u b lic a tio n . Another meeting o f the Talc Sub-Committee has been scheduled fo r March 31, 1976 to discuss the fo llo w in g : 1, Discussion o f fu rth e r CTFA s tra te g y , vis a v is , Mt. Sinai e.g, - data exchange, methodology o f analysis. 2. CTFA analysis o f FDA pick-up samples from th e ir 1975 survey, 6, Sandland, Chairman Talc Sub-Committee Goodhue WCD 000241